Aquestive Therapeutics, Inc. AQST Accrued Progress Collections and Price Adjustments
Accrued Progress Collections and Price Adjustments at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s accrued progress collections and price adjustments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s accrued progress collections and price adjustments?
- Aquestive Therapeutics, Inc. (AQST) reported accrued progress collections and price adjustments of $19.12M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s accrued progress collections and price adjustments changed year-over-year?
- Aquestive Therapeutics, Inc.'s accrued progress collections and price adjustments decreased by 3.2% year-over-year, from $19.74M to $19.12M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s accrued progress collections and price adjustments?
- Over 5 years (2020 to 2025), Aquestive Therapeutics, Inc.'s accrued progress collections and price adjustments has grown at a 39.8% compound annual growth rate (CAGR), from $3.63M to $19.39M.